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A BST R AC T   
 
Aim: The umbilical cord (UC) is a rich source of mesenchymal stem cell (MSC) isolation. Since the MSCs 
isolated from here have high self-renewal capacity and differentiation potential, production through 
biofabrication is essential for clinical treatments. For the cells to be stored for a long time and presented ready 
for use, encapsulation is required. In this study, UC-MSC cells were encapsulated with alginate using three 
different methods: alginate drop, alginate coating, and alginate sphere.  
Methods: The cell viability, live/dead cell ratio, and colony formation capacities of the encapsulated cells 
were examined for 14 days.  
Results: In the study, it was found that the most effective method was the alginate sphere form and that the 
structure of the cells should be preserved by injecting them into biomaterials in encapsulation. Colony 
formation potential was found to be high in biomaterials with alginate spheres.  
Conclusion: As a result, the preservation of UC-MSC cells with alginate sphere encapsulation via 
biofabrication and their clinical use availability may be beneficial for treating of many diseases. 
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Introduction 
Mesenchymal stem cells (MSCs) are 
multipotent cell types obtained from a wide 
variety of tissues such as adipose tissue, bone 
marrow, dental pulp, placenta, and umbilical 
cord [1]. MSCs are different from other cells 
with its features of proliferation, differentiation, 
and self-renewal. Although it plays a vital role 
in development during the embryonic period, 
they now have the therapeutic potential [2–4]. 
MSCs have been challenging a role 
therapeutics in clinical ameliorating from 
cancer to central nervous system diseases [5,6]. 
MSCs can inhibit the immune system, increase 
cell proliferation, induce angiogenesis, or 
migrate toward damaged tissues. Furthermore, 
the multifunctional capabilities of MSCs 
increase their use in both the medical and 
pharmaceutical industries. In the world, stem 
cell and cellular therapy companies make 
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significant investments in obtaining MSCs and 
keeping them for a long time without disturbing 
their activity [7]. The umbilical cord (UC) is a 
non-invasive and ethically trouble-free source 
of stem cells, as it is isolated from tissue taken 
at birth. UC contains MSC cells with high 
availability and high growth capacity of 
embryonic origin. Compared to cells taken 
from adult tissues, UC cord cells are a very 
attractive resource as they have spread faster 
[8,9].  
Isolation processes of MSCs from UC are 
laborious and higher costly, require a great deal 
of experience. Isolations can be made 
differently; the most used methods are 
enzymatic digestion for separation or explant 
culture method [10]. After isolation of MSCs, 
studies are carried out to be stored for a long 
time and used therapeutically. Biopolymers 
with high biocompatibility such as alginate, 
chitosan, agarose, collagen, poly(lactic-co-
glycolic acid) (PLGA), poly(ethylene glycol) 
(PEG), (poly(lactic acid) (PLA) and 
poly(glycolic acid) (PGA) are used for 
microencapsulation of MSCs [11]. Alginate is a 
natural polysaccharide and a biopolymer with 
high biocompatibility, stability, and non-
antigenicity. Alginate shows gelation by 
crosslinking with calcium ions. These formed 
hydrogels are used as encapsulation material 
and can be produced by bio fabrication in 
various applications. Their use in medicine and 
pharmacy has been increasing rapidly in recent 
years due to its non-toxicity and gelling. 
Microencapsulation of UC-derived MSCs with 
a highly biocompatible polymer such as 
alginate after isolation may increase their use in 
stem cell treatments. New microencapsulation 
methods should be developed in order for UC-
derived MSCs to maintain their rich content and 
rapid growth capacity without losing their 
capabilities. In this study, we investigated the 
colony formation potential of UC-MSCs in the 
encapsulation of alginate 
 
Materials and Methods 
 
Cell culture and conditions 
Human umbilical cord-derived mesenchymal 
stem cells (UC-MSC) were provided by ATCC 
(PCS-500-010). Cells were cultured in DMEM 
(Dulbecco's Modified Eagle's medium) (Gibco, 
USA) supplemented with 15% fetal bovine 
serum (FBS; Gibco), 2 mM L‐glutamine, and 
100 U/mL penicillin, and 100 µg/mL 
streptomycin, at 37 °C in a humidified 
atmosphere containing 5% CO2. The medium 
was changed every three days.  
 
Preparation of alginate constructs  
Sodium alginate was purchased from Sigma 
(W201502) and dissolved with sterile PBS 
(phosphate-buffered saline) solution. Alginate 
solution was modified prepared different 
concentration as 0.625%, 1.25% and 2.5% w/v 
via encapsulation methods [12]. Each solution 
was passed through 0.45 sterile filters. Sterile 
calcium chloride solutions (2% w/v) were 
prepared and used for reducing agent to 
crosslink the alginate at 25 °C. Calcium and 
alginate complex was left for 5 minutes to form 
a hydrogel, and then it was taken into DMEM 
medium. The alginate encapsulation’s 
rheological behaviors were determined using a 
rheometer (HAAKE MARS 40 Rheometer, 
Invitrogen). The viscosity measurements were 
done at 25ºC and calculated by shear rate. 
Alginate deformation rate was calculated as the 
change in viscosity over 14 days without cells 
at 37 °C. 
 
Encapsulation of UC-MSC 
Experimental design on encapsulation was 
included in Figure 1. The encapsulation method 
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was modified by the amount of alginate and   
calcium and according to the selected cell [13]. 
Alginate Drop: Alginate solution (1.25%) and 
UC-MSC cells (500 cells) were mixed. 10 µL 
volume of the mixture was dropped into 
calcium solution. It was incubated for 5 minutes 
to crosslink, and after washing with PBS, 100 
µL of cell medium was added into each well of 
the 96-well plate. Alginate Coating: 50 µL 
alginate solution (1.25%) was coated into each 
well of the 96-well plate, and 50 µL calcium 
solution was added to crosslink. After the 
washing with PBS, UC-MSC cells (500 cells) 
were seeded with 100 µL of cell medium was 
added into each well of the 96-well plate. 
Alginate Sphere: 10 µL alginate solution 
(1.25%) was added into each well of the 96-
well plate, and 25 µL calcium solution was 
added to the alginate. After the crosslinking, 
UC-MSC cells (500 cells) were injected into the 
alginate sphere, and 100 µL of cell medium was 
added into each well of the 96-well plate. 
 
Cell viability and live/dead cells 
The encapsulated UC-MSC cells were 
incubated for 7 days and 14 days. At the end of 
the incubation, alginate encapsulations were 
dissolved in sodium citrate-EDTA buffer (55 
mM Na-citrate, 20 mM EDTA). Each well was 
incubated with 10 µL MTT solution (MTT; 
Vybrant, Invitrogen) for 4 hours at 37°C, 5% 
CO2. After incubation, solubilization was done 
in 100 µL SDS buffer to formazan precipitates 
[14]. Color changes were measured at 570 nm 
using a microplate reader (Epoch, Biotek). 
Dissolved cells were suspended in PBS and 




The encapsulated cells were examined 
morphologically [14] at the end of the 14th day 
under an inverted microscope (Zeiss Axiovert, 
Germany). The areas inside the capsules in the 
cells were focused. The ratio of colony-forming 




Data were analyzed with GraphPad Prism 
software (GraphPad Inc., San Diego, CA, 
USA). All values were presented as mean ± SD. 
Between study groups, the obtained data were 
compared by using a non-paired t-test and two-
way ANOVA.  Differences were considered 
statistically significant if the p-value was less 
than 0.05.  
 
Results 
Alginate viscosity was measured in a shear rate 
range of 1–1000 s-1 by increasing the shear rate 
every 10 s for 1 min. For 2.5% alginate, the low 
shear viscosity at 25 °C was found to be 282 
mPa s; for 1.25% alginate, the moderate shear 
viscosity at 25 °C was 365 mPa s; for 0.625% 
alginate, the high shear viscosity at 25 °C was 
687 mPa s (Fig 2a). The effect of shear stress 
on the viscosity was different for each alginate. 
In alginate deformation, the deformation rate 
was significantly higher in the coating of 
0.625% alginate on the well surface (p<0.0001) 
while there is no deformation in the other 
concentration for encapsulation with drop and 
sphere of alginate (Fig 2b). Cell viability 
activities of UC-MSC cells were checked on the 
7th day, as the adhesion and attachment of stem 
cells were difficult. A certain number of stem 
cells were planted in each well, it was observed 
that the cells maintained their viability in the 
alginate drop group (p>0.1350), but cell 
viability decreased significantly in the alginate 
coating group compared to the control 
(p<0.0001).      The alginate     sphere      group  
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observed that the cell viability levels increased 
significantly compared to the control group 
(p<0.0098, Fig 3a). The live and dead cell 
proportions of the UC-MSC cells after 14 days 
were evaluated. It was observed that the number 
of dead cells increased slightly in the alginate 
drop group compared to the control group 
(p<0.0166), and the change in the number of 
live cells was not significant (p>0.0594). It was 
observed that the number of dead cells 
increased significantly in the alginate coating 
group (p<0.0001) and decreased in the alginate 
coating group of living cells compared to the 
control group (p<0.0001). It was observed that 
the number of live cells increased significantly 
in the alginate sphere group compared to the 
control group (p<0.0403), and there was no 
change in the number of dead cells (p>0.1708, 
Fig 3b). 
The colony formation potential of UC-MSC 






















microscopically (Fig 4). Since cells in the 
control group tend to adhere to cell culture 
plates, their colony-forming potential is limited. 
The colony-forming potential of cells in the 
alginate drop increased significantly compared 
to control group cells (p<0.0002). When the 
alginate coating group was compared with the 
control group, it was observed that there was no 
change in colony formation potential 
(p>0.3780). The colony-forming potential of 
UC-MSC cells in the alginate sphere increased 
significantly compared to control group cells 
(p<0.0001, Fig 4b). 
 
Discussion 
MSCs are rich in content, and they interact with 
other cells through bioactive mediators in their 
structure, such as hormones, growth factors, 
cytokines, and extracellular vesicles that exert 
angiogenic and anti-inflammatory effects. 
MSCs     can    show  immunosuppressive, anti- 
 
Figure 1. Experimental design for the umbilical cord- mesenchymal stem cells (UC-MSCs). 
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Figure 2. Alginate viscosity and deformation. 
 
Figure 3. Effects of alginate encapsulation models in cell viability and live/dead cell ratio on UC-
MSC. 
 
Figure 4. Effects of alginate encapsulation models in cell colony formation on UC-MSC. 
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apoptotic, anti-fibrotic effects on other cells. To 
benefit from these potentials MSC cells, are 
being developed, and new therapeutic dosing 
studies with encapsulation are carried out in this 
area for cellular therapy methods [15,16]. For 
MSC cells to be used therapeutically, there is a 
need for an encapsulation system that can 
maintain their viability for a long time. 
Especially in MSCs, UC-derived cells that are 
small amount but have the most incredible 
growth ability and contain important biofactors 
that are essential. UC-MSCs are isolated from 
umbilical cord blood or cord tissue. MSC 
isolation from UC tissue requires a lengthy 
dissection step, and opening the umbilical cord 
and manual removal of the vessels before 
mincing Wharton jelly is time-consuming and 
increases the risk of contamination. UC-MSCs 
are essential to be isolated under GMP 
conditions and stored for long periods [17]. UC-
MSCs have significant enhancements, have 
high proliferation potentials, vast 
differentiation potentials, and enhanced 
immune modulation properties [18,19]. For 
these reasons, UC-MSCs have high therapeutic 
potential and have an important place in clinical 
trials worldwide [20,21]. Encapsulation of cells 
is a technique that enables living cells to be 
confined with unique biopolymeric materials 
and use them in the potential treatment of 
various human diseases [22]. There are many 
studies on low immunity for cell encapsulation 
and the development of biomaterials to protect 
stem cells [23]. It is crucial to develop a method 
for both the isolation of stem cells and their 
long-term storage. The properties and shapes of 
biomaterials during production are essential for 
clinical applications of cell encapsulation of 
stem cells [24,25]. Many in vivo studies 
showed that the encapsulation and 
administration of stem cells produced from 
different sources (such as bone marrow, 
adipose tissue) with alginate [26]. For example, 
alginate-encapsulated human BM-MSCs have 
demonstrated a therapeutically curative effect 
at the infarct site in the rat myocardial infarction 
model [27]. Another study showed that 
alginate-encapsulated MSCs remained viable 
for 30 days and did not lose their therapeutic 
effect when administered subcutaneously to 
mice [28]. Similarly, in our study, we found that 
the alginate sphere group’s vitality was high on 
the 14th day. On the other hand, some 
suggestions would be beneficial to use a single 
cell microgel encapsulation approach for MSC. 
In systemic applications of MSC, it provides 
diffusion limitations in protecting stem cells 
against hypoxic effects and facilitating 
molecules released from the cell [29]. There are 
still restrictive studies regarding colony 
formation in stem cells in single-cell 
capsulations [30]. Colony formation of 
mesenchymal stem cells (maybe called 
spheroidization) exhibits improved therapeutic 
potential in vitro, but if spheroids fail to attach 
in the environment, they leave control of cell 
function to the extracellular matrix and 
potentially limit development time. Using 
biomaterials is supported by spheroid cell 
transmission, cell retention and stem cells’ 
functions [31]. In the study using the 
osteoarthritis model, it was reported that 
allogeneic rat MSC cells survived longer when 
encapsulated in alginate and showed metabolic 
activity for at least eight weeks in vivo [32]. In 
this study, high and low weight alginate and 
allogenic MSC cells were first mixed in the 
form of beads and marked with gadolinium for 
monitoring. It has a similar structure to the drop 
alginate complexes in our study and is formed 
with different cells. The production of cell-
alginate microcapsules containing MSC cells in 
a standardized, safe manner must certainly 
establish the "ready-to-use" potential in clinical 
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practice [29]. Some researchers, MSC cells 
isolated from the umbilical cord Wharton jelly 
were encapsulated with alginate, and 
differentiation into neuron-like cells was 
examined. The study showed that alginate 
could effectively induce neuronal 
differentiation in a three-dimensional cell 
culture system by protecting cells [33]. In a 
different study, MSC cells isolated from 
Wharton jelly were encapsulated with alginate, 
and the interleukins, chemokines, growth 
factors, and soluble forms of adhesion 
molecules released into the environment were 
investigated. It has been reported that alginate 
does not change cells’ morphological properties 
and can provide protein circulation in the 
general life cycle [34].  
 
Conclusion 
For bio fabrication studies, UC-MSC provides 
dissemination of research on encapsulation. 
The alginate sphere in our study was created 
with the logic of microencapsulation. It has 
been determined that the cells placed in the 
capsules can form a better colony. When the 
biodegradable alginate system is opened in the 
tissues, these colonies’ potential to form new 
cells there will be higher. This method may be 
more useful for biofabrication studies. For 
smaller microencapsulation studies, these data 
will shed light on future studies. 
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